Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2017 /
Reviewing LORELEI, mindACT and ExteNET trials in breast cancer

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.09.17
Views: 772

Prof Miguel Martin - Hospital General Universitario Gregorio Marañón, Madrid, Spain

Prof Martin talks with ecancer at the ESMO 2017 Congress and reviews a breast cancer session that examined three trials:

- The ExteNET trail, looking at the use of neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer following trastuzumab-based therapy. 

- The MINDACT study, confirming the value of genomic profiling for patients with early breast cancer with zero to three positive lymph nodes. 

- The LORELEI trial, stating that adding taselisib to letrozole before surgery significantly improved outcomes for patients with early breast cancer that was both oestrogen receptor positive and HER2-negative.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence